ArticleClinical case reports2023
Visceral leishmaniasis complicated by hemophagocytic lymphohistiocytosis: A case report from a nonendemic area.
Article in Clinical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 4 citations in OpenAlex.
- Secondary Hemophagocytic Lymphohistiocytosis Triggered by Visceral Leishmaniasis Due toReports (MDPI) · 2026Article
- mNGS-Assisted Diagnosis of Visceral Leishmaniasis Presenting as Hemophagocytic Lymphohistiocytosis: Two Cases Confirmed by rK39.Infection and drug resistance · 2026Article
- Clinical and PET/CT metabolic imaging characteristics across the evolving spectrum of visceral leishmaniasis and associated hemophagocytic lymphohistiocytosis.Frontiers in immunology · 2026Article
- Contrasting outcomes of visceral leishmaniasis in two patients with membranous nephropathy receiving immunosuppressive therapy: a case report.Frontiers in immunology · 2026Article
- Cutaneous leishmaniasis in a renal transplant patient: Diagnostic challenges in a non-endemic setting.IDCases · 2025Article
- Visceral leishmaniasis complicated by hemophagocytic lymphohistiocytosis: A case report from a nonendemic area.Clinical case reports · 2023Article
- Assessment of nutritional status among post-kala-azar dermal leishmaniasis patients in endemic areas of northern West Bengal, India.Tropical parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Key Clinical Message: Visceral leishmaniasis and hemophagocytic lymphohistiocytosis share many features in common and may coincide in the same patient. Timely diagnosis and management of visceral leishmaniasis could save patients from unnecessary toxic treatment. Abstract: Visceral leishmaniasis and hemophagocytic lymphohistiocytosis share many clinical features in common and may coexist in the same patient. Visceral leishmaniasis should be promptly ruled out in patients coming from endemic areas before starting immunosuppressive therapy for hemophagocytic lymphohistiocytosis. The mainstay treatment, in this case, is anti-leishmania medications preferably liposomal amphotericin-B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.